1Mason PJ, Freedman JE, Jacobs AK. Aspirin resistance: current concepts. Rev Cardiovasc Med, 2004,5:156-163.
2Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation, 2004,20:109:166-171.
3Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation, 2004,29:109:3171-3175.
同被引文献4
1Smith SC, Feldman TE, Hirshfeld JW, et al. ACC/ AHA/SCAI 2005 guideline update for percutaneous coronary intervention., a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention ) Circulation, 2006,113 : e166-286.
2Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation, 2007, 115: 813-818.
3The CURRENT-OASiS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med, 2010, 363: 930-942.
